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Abstract
Kaposi’s sarcoma (KS) is a mesenchymal tumour, which is caused by Kaposi’s sarcoma herpesvirus (KSHV) and develops
under inflammatory conditions. KSHV-infected endothelial spindle cells, the neoplastic cells in KS, show increased
invasiveness, attributed to the elevated expression of metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2). The
majority of these spindle cells harbour latent KSHV genomes, while a minority undergoes lytic reactivation with subsequent
production of new virions and viral or cellular chemo- and cytokines, which may promote tumour invasion and
dissemination. In order to better understand KSHV pathogenesis, we investigated cellular mechanisms underlying the lytic
reactivation of KSHV. Using a combination of small molecule library screening and siRNA silencing we found a STE20 kinase
family member, MAP4K4, to be involved in KSHV reactivation from latency and to contribute to the invasive phenotype of
KSHV-infected endothelial cells by regulating COX-2, MMP-7, and MMP-13 expression. This kinase is also highly expressed in
KS spindle cells in vivo. These findings suggest that MAP4K4, a known mediator of inflammation, is involved in KS aetiology
by regulating KSHV lytic reactivation, expression of MMPs and COX-2, and, thereby modulating invasiveness of KSHV-
infected endothelial cells.
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Introduction
Kaposi’s sarcoma (KS) is a mesenchymal tumour caused by
Kaposi’s sarcoma herpesvirus (KSHV) [1], which originates from
blood and lymphatic vessels and develops under the influence of
inflammatory cytokines [2–4]. Local or systemic inflammation and
immunosuppression are important additional risk factors [5,6]. In
addition to KS, KSHV is involved in the pathogenesis of primary
effusion lymphoma (PEL) [7], and the plasma cell variant of
multicentric Castleman’s disease (MCD) [8].
KS is characterised by multiple patch, plaque or nodular lesions
on the skin of the extremities or involving the mucosa and visceral
organs [9]. KSHV-infected spindle cells, which were shown to be
of vascular or lymphatic endothelial origin, represent the main
proliferative element in KS and are the distinctive histological
signature of advanced KS tumours [10,11]. The lesions also
contain slit-like neovascular spaces, which represent aberrant new
vessels [5,12]. KS spindle cells were shown to have increased
invasiveness [13], which has been attributed to the enhanced
expression of several matrix metalloproteinases (MMPs) [14],
including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, and
MMP-13 [13,15,16]. MMPs are zinc-dependent endopeptidases
involved in extracellular matrix remodelling during tumour
progression, invasion and metastasis [17,18]. In addition to
MMPs, the key enzyme for inducible prostaglandin synthesis –
cyclooxygenase 2 (COX-2) [19] – has also been implicated in KS
progression and invasion [20]. Increased COX-2 expression in
inflammation-driven tumours contributes to neoangiogenesis and
activates MMPs, which promote invasiveness [21,22]. COX-2 is
highly expressed in KS tumour tissue and is involved in KS
pathogenesis [20,23,24]. Several KSHV proteins were shown to
enhance COX-2 expression, including K15 [25], and vGPCR
[26]. This could explain how KSHV may increase COX-2 gene
expression.
In KS tumours, the majority of KSHV-infected cells harbour
latent viral genomes, which are characterised by a restricted viral
gene expression pattern that involves the major latent nuclear
antigen LANA, homologues of a cellular D-type cyclin and a
FLICE inhibitory protein, v-Cyclin and v-FLIP, respectively, and
12 viral miRNAs [6,27]. However, a minority of infected cells
show evidence of productive (‘lytic’) replication and produce not
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only new virions [28], but also secrete viral or cellular cyto- or
chemokines [6,10,27,29,30]. These are thought to promote the
pathological angiogenesis typical for KS lesions, increased
invasion, and tumour dissemination [31]. Epidemiological findings
also indicate that the prophylactic use of ganciclovir, which
inhibits KSHV lytic replication, may reduce the incidence of KS
in AIDS patients [32]. In addition, it is thought that the long-term
persistence of KSHV in vivo may require periodic reactivation from
latency and reinfection of new cells [33]. Experimentally,
reactivation of KSHV from latency can be initiated by various
chemical agents: these include phorbol esters and histone
deacetylase inhibitors, which lead to chromatin remodelling and
activation of the viral replication and transcription activator (RTA)
[34–37]. So far, several signalling pathways were reported to be
involved in the reactivation of KSHV from latency: PKCd [38], b-
Raf/MEK/ERK [39], PKA [40], Notch and RBP-Jk [41,42], p38
and JNK [43], Pim-1 and Pim-3 [44], PI3K and Akt [45], TLR7/
8 signalling [46] and others.
Given the importance of the KSHV lytic cycle in KS
pathogenesis and the angiogenic and invasive phenotype of
KSHV infected cells, we aimed at identifying ‘druggable’ cellular
kinases required for KSHV reactivation from latency. To this end,
we screened a library of kinase inhibitors and found the STE20
kinase family member MAP4K4 to be a novel mediator of KSHV
lytic reactivation. MAP4K4 is known to play an important role in
inflammation, insulin resistance, and invasiveness of several
malignancies [3,47–55]. We found that MAP4K4 regulates the
expression of COX-2, MMP-7 and -13, and thereby modulates
the invasiveness of KSHV infected primary and immortalized
endothelial cells. Moreover, we found MAP4K4 to be strongly
expressed in KSHV-infected endothelial spindle cells in KS tissue,
consistent with a role of MAP4K4 in KS pathogenesis.
Results
MAP4K4 promotes reactivation of KSHV from latency
Productive replication of KSHV in infected individuals is
thought to contribute to viral persistence and the pathogenesis of
this virus [56,57]. Activation of several cellular kinases, involved in
different signalling pathways, promotes viral reactivation [58,59].
In order to identify novel ‘‘druggable’’ cellular kinases required for
KSHV reactivation we screened a library of 486 small molecule
kinase inhibitors (figure 1A) in a KSHV reactivation assay based
on Vero cells infected with the recombinant KSHV strain
rKSHV.219 (VK.219) [60]. The activation of productive replica-
tion cycle was achieved by treatment with Na-butyrate and
infection with a baculovirus expressing KSHV immediate-early
protein RTA. Toxicity of the compounds was determined by
crystal violet staining of VK.219 and HEK293 cells after
treatment. As a result, 105 compounds showed moderate to
strong effects on virus production and infectivity without being
toxic. Among them, 92 compounds were able to directly inhibit
KSHV lytic protein expression in VK.219 cells. The results were
validated in BCBL1 [61], and KSHV-infected EA.hy 926 [62]
cells. As a result, we identified 18 compounds able to inhibit
KSHV lytic protein expression in all three cell lines (figure S1A).
Interestingly, among them were 11 compounds identical to, or
derived from, known p38 MAP kinase inhibitors, in line with
earlier reports on the role of this kinase in KSHV reactivation
[43,58]. When comparing the effects of commercially available
p38 inhibitors with compounds in the VICHEM library, we noted
that p38 inhibitors SB202190, SB203580, VX745, SKF86002,
SB220025, and a derivative of SB220025 (VI18802) differed in
their ability to block KSHV reactivation, as shown by their effect
on the expression of KSHV envelope glycoprotein K8.1
(figure 1B), although their ability to inhibit the phosphorylation
of MK2, a p38 target, seemed comparable (figure 1B). Of these
compounds, SB220025 was the most potent with regard to
inhibiting K8.1 expression (figure 1B) or virus production (not
shown). To validate the effect of SB220025 on KSHV reactiva-
tion, we titrated this compound in KSHV-infected endothelial
cells (KSHV-infected EA.hy 926) and found it to inhibit KSHV
reactivation at submicromolar concentrations (figure 1C). We
then determined which other cellular kinases are inhibited by
SB220025 and its derivative VI18802. Compound SKF86002,
although a strong inhibitor of lytic reactivation, was not included
in this comparison, as it reduced the levels of total MK2
(figure 1B). We used a commercial screening assay that measured
the ability of these compounds to compete with an immobilized
ligand for binding to a panel of 442 recombinant kinases in an in
vitro assay (see www.discoverx.com). The list of cellular kinases
inhibited by SB220025 and VI18802 is shown in a table presented
in figure S1B, which also includes previously published data on
compounds SB203580, SB202190 and VX745 [63].
To explore if, apart from p38, any of the other kinases inhibited
by SB220025 could account for the strong inhibition of KSHV
reactivation observed with this compound, we used small molecule
inhibitors or siRNAs against CSNK1D, CSNK1E, CSNK1A1L,
MINK, CDC2L1/2, JNK1, MAP4K4, STK36 and TNIK (data
not shown). As a result of these experiments we identified the
upstream MAP kinase MAP4K4 (data not shown), a member of
the STE20 kinase family, which has previously been shown to be
involved in inflammation, response to LPS, inflammation-depen-
dent insulin resistance of peripheral tissues, and also invasiveness
of several types of cancer cells [47,48,53,64,65].
In order to explore if MAP4K4 affected KSHV reactivation in a
cell type that is known to be infected by KSHV in vivo, we used a
pool of siRNAs to silence MAP4K4 expression in the immortal-
ized HUVEC derived cell line EA.hy 926 [62], which we had
stably infected with rKSHV.219. As shown in figure 2, silencing
of MAP4K4 in these cells significantly reduced production of
infectious viral progeny by more than 60% (figure 2A), as well as
the expression of immediate-early (RTA), early (KbZIP, ORF45)
and late (K8.1) lytic proteins (figure 2B). The effect on K8.1
expression was confirmed using four individual siRNAs targeting
MAP4K4, all of which were able to reduce MAP4K4 and K8.1
levels (figure S2A, B). In contrast to other lytic KSHV proteins,
the expression of the viral homologue of IL-6, vIL-6, was slightly
increased by MAP4K4 knockdown (figure 2B). vIL-6 expression
is known to be regulated independently of the productive
replication cycle [66] and may therefore not be affected by
Author Summary
Kaposi’s sarcoma (KS) is a tumour caused by Kaposi’s
sarcoma herpesvirus (KSHV) and dysregulated inflamma-
tion. Both factors contribute to the high angiogenicity and
invasiveness of KS. Various cellular kinases have been
reported to regulate the KSHV latent-lytic switch and
thereby virus pathogenicity. In this study, we have
identified a STE20 kinase family member – MAP4K4 – as
a modulator of KSHV lytic cycle and invasive phenotype of
KSHV-infected endothelial cells. Moreover, we were able to
link MAP4K4 to a known mediator of inflammation and
invasiveness, cyclooxygenase-2, which also contributes to
KSHV lytic replication. Finally, we could show that MAP4K4
is highly expressed in KS lesions, suggesting an important
role for this kinase in tumour development and invasion.
MAP4K4 Promotes KSHV Reactivation and Invasiveness
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Figure 1. Identification of cellular kinases involved in KSHV reactivation. (A) Schematic of the screen performed to identify cellular kinases
important for KSHV lytic reactivation. In total, 486 compounds were applied to VK.219 and HEK293 cells to exclude toxic substances, 323 were
screened for inhibition of KSHV production after lytic cycle induction in VK.219 cells, 105 were tested in Western blot analysis for inhibition of KSHV
lytic protein expression in VK.219 cells, 92 were validated in Western blot analysis for inhibition of KSHV lytic protein expression in BCBL1 and EA.hy
rKSHV.219 cells, out of which 18 compounds proved to be efficiently blocking KSHV production and lytic protein expression, without being generally
toxic. 11 of them were known to target p38 MAPK or derived from p38 inhibitors. (B) Effect of p38 inhibitors on KSHV lytic protein expression. EA.hy
rKSHV.219 cells were treated with p38 inhibitors at the indicated concentrations one hour prior to the lytic cycle induction. Forty-eight hours after
lytic reactivation the cells were lysed and analysed for phospho- and total protein expression. Western blot analysis shows phospho- and total p38
and MK2 expression, and KSHV lytic protein K8.1. The blot is one representative of three independent experiments with similar results. (C) Titration of
MAP4K4 Promotes KSHV Reactivation and Invasiveness
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MAP4K4 silencing. Consistently with the observed decrease in
virus production and lytic protein expression, MAP4K4 depletion
also reduced KSHV genome replication (figure 2C), similarly to
foscarnet, an inhibitor of KSHV DNA polymerase [67]. However,
while foscarnet only inhibited the expression of a late viral gene
(K8.1), MAP4K4 silencing also affected early KSHV gene
(KbZIP) expression (figure 2D), suggesting that this kinase exerts
its effect early in the replication cycle. To control whether
MAP4K4 knockdown affects transduction or expression of
baculovirus RTA, we evaluated the levels of RTA mRNA
transcripts before and after MAP4K4 depletion in cells not
infected with KSHV that had been treated with baculovirus RTA
alone or in combination with Na-butyrate. In these cells, RTA
expression was not dependent on MAP4K4 presence (figure
S2C–D). Taken together, the observed decrease in KSHV titre,
lytic protein expression, and replication in the absence of
SB220025 in EA.hy rKSHV.219 cells. EA.hy rKSHV.219 cells were treated with the indicated concentrations of SB220025 or DMSO as a vehicle control
one hour before lytic cycle induction. Forty-eight hours after lytic reactivation the cells were analysed for phospho- and total p38, MK2 and K8.1
protein expression. The blot is one representative of three independent experiments with similar results.
doi:10.1371/journal.ppat.1003737.g001
Figure 2. MAP4K4 promotes the lytic reactivation of KSHV. MAP4K4 was silenced with siRNA in EA.hy rKSHV.219 or HuAR2T rKSHV.219 cells
twenty-four hours prior to the induction of the viral lytic cycle. Forty-two hours after activating the lytic cycle with Na-butyrate and RTA transduction
(see Material and Methods) cells and supernatants were harvested for subsequent analysis. (A) KSHV titre before and after MAP4K4 knockdown.
HEK293 cells were infected with viral supernatants from siRNA treated EA.hy rKSHV.219 cells. Production of infectious virus particles was quantified by
counting GFP-positive HEK293 cells forty-eight hours after infection. The bar graph shows means 6SD of five independent experiments. The p value
was determined using a One-way ANOVA with Tukey’s multiple comparison post-test. p,0.01 (**). (B) Western blot analysis of KSHV lytic protein
expression. EA.hy rKSHV.219 cells were lysed, cell extracts resolved by SDS-PAGE and the indicated KSHV proteins have been detected with specific
antibodies. The blot is one representative of seven independent experiments with similar results. (C) KSHV genome copy number after MAP4K4
depletion or foscarnet treatment. HuAR2T rKSHV.219 cells were lysed, DNA extracted and KSHV genome copy number was evaluated by qPCR
analysis. The bar graph shows means 6SD of three independent experiments. The p value was determined using a One-way ANOVA with Tukey’s
multiple comparison post-test. p,0.001 (***). (D) Western blot analysis of KSHV lytic protein expression after MAP4K4 depletion or Foscarnet
treatment. HuAR2T rKSHV.219 cells were lysed, cell extracts resolved by SDS-PAGE and the indicated KSHV proteins detected with specific antibodies.
The blot is one representative of three independent experiments with similar results.
doi:10.1371/journal.ppat.1003737.g002
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MAP4K4 suggests that this kinase contributes to the successful
completion of the KSHV lytic programme.
MAP4K4 is required for the invasiveness of endothelial
cells
MAP4K4 is also known to promote tumour cell migration,
invasion, and loss of adhesion [49,68]. KS tumour derived cells
have been reported to show an invasive phenotype [69]. This
phenomenon can be studied in vitro in a matrigel-based invasion
assay, in which uninfected HuAR2T, a conditionally immortalized
HUVEC cell line [70], fails to invade into matrigel, whereas
HuAR2T cells infected with rKSHV.219 show increased inva-
siveness after the treatment with Na-butyrate to induce the KSHV
lytic replication cycle (figure 3A–B). Thus, lytic reactivation of
the virus promotes invasiveness of these immortalized endothelial
cells infected with KSHV. As we observed that MAP4K4 supports
the KSHV lytic cycle (figure 2) and since it had been reported to
Figure 3. MAP4K4 is required for the increased invasiveness of KSHV-infected endothelial cells. Uninfected HuAR2T cells, or HuAR2T
cells stably infected with rKSHV.219 were treated with Na-butyrate and a baculovirus vector expressing RTA, or left untreated, for twenty-four hours
with subsequent starving for twelve hours in EBM2 basal medium supplemented with 2% FBS. Equal numbers of cells were seeded on growth factor
reduced Matrigel invasion chambers. After twenty-four hours invaded cells were fixed and stained with DAPI. (A) Representative images of invasive
cells before and after induction of the lytic cycle. (B) Invasion score measured by quantification of DAPI signal from invasive cells. The bar graph
shows means 6SD of invasion scores of three independent experiments. (C) Representative images of invasive KSHV-infected cells before and after
MAP4K4 depletion and after induction of the lytic replication cycle. MAP4K4 or control siRNA were transfected twenty-four hours prior to the
induction of the lytic replication cycle. (D) Invasion score presented as means 6SD of three independent experiments. The p values were determined
using a One-way ANOVA with Tukey’s multiple comparison post-test. p.0.05 (ns); p,0.05 (*); p,0.01 (**); p,0.001 (***); p,0.0001 (****). (E) Western
blot analysis of MAP4K4 and KSHV KbZIP early lytic protein expression.
doi:10.1371/journal.ppat.1003737.g003
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be a promigratory kinase [49], we investigated if its silencing might
affect the ability of KSHV-infected endothelial cells to invade
matrigel. Indeed, after silencing of MAP4K4 expression with
siRNA, KSHV-infected HuAR2T endothelial cells failed to invade
matrigel beyond the levels seen in uninfected control cells
(figure 3C–D). MAP4K4 and KSHV lytic protein expression
was controlled by Western blot analysis as presented in figure 3E.
Together, these data suggest a role for MAP4K4 signalling in the
KSHV-dependent invasiveness of infected endothelial cells.
Identification of genes whose expression is regulated by
MAP4K4 signalling
In an attempt to understand how MAP4K4 promotes lytic
reactivation and leads to the increased invasiveness of KSHV-
infected endothelial cells we compared the transcriptome of
reactivated KSHV-infected HuAR2T cells, in which the expres-
sion of MAP4K4 had been silenced with siRNA, with KSHV-
infected, reactivated HuAR2T cells treated with control siRNA.
We were able to identify 54 cellular genes that showed at least a
1.5-fold decrease in their expression levels after MAP4K4
knockdown in HuAR2T rKSHV.219 undergoing viral reactiva-
tion as compared to control siRNA treated, reactivated HuAR2T
rKSHV.219 cells in at least two out of three independent
experiments (figure 4A). Successful knockdown of MAP4K4,
and the subsequent inhibition of lytic gene expression, was
controlled by Western blot analysis (figure S2E). Among the
cellular genes regulated by MAP4K4 silencing in KSHV-infected
endothelial cells were three that have previously been reported to
contribute to the invasive phenotype of tumour cells: PTGS2,
encoding cyclooxygenase 2 (COX-2), and the genes coding for
matrix metalloproteinases 7 and 13 (MMP-7 and MMP-13)
(figure 4A). In order to validate the results of the transcriptome
analysis, the expression levels of COX-2 were evaluated by qPCR
and Western blot analysis before and after the induction of the
lytic cycle. As shown in figure 4B–C, COX-2 mRNA and
protein expression is upregulated following induction of the viral
lytic cycle and can be reduced by silencing MAP4K4. Likewise,
we could show that the expression of both MMP-7 and MMP-13
mRNAs increased after the induction of the lytic cycle and was
significantly reduced after MAP4K4 depletion (figure 4B).
These data support the notion that MAP4K4 may mediate the
increased invasiveness of KSHV-infected endothelial cells due to
its ability to modulate not only COX-2, but also MMP-7 and
MMP-13 expression.
MMP-7 and MMP-13 are required for KSHV-driven
endothelial cell invasiveness
KS cells are known to express high levels of MMP-1, -2, -3, -7, -
9, -13, -19, and previous reports suggest that some of these
metalloproteinases may contribute to the invasive phenotype of
the tumour [14,16,71,72]. Overexpression of MMP-7 has been
reported in several other malignancies [73–75], and its depletion
with siRNA resulted in a significant decrease in the invasive
potential of different cancer cell types [76–78]. Similarly, MMP-13
has been reported to confer the ability to penetrate basement
membranes and ECM upon malignant cells [79]. Given these
proinvasive properties of MMP-7 and MMP-13, and taking into
account the ability of MAP4K4 to regulate their expression
(figure 4), we addressed the involvement of these metalloprotei-
nases in the invasiveness of KSHV-infected cells in a matrigel-
based invasion assay. We found that depletion of both MMP-7 and
MMP-13, similarly to MAP4K4 knockdown, led to a significant
reduction of the number of invasive KSHV-infected endothelial
HuAR2T cells following activation of the viral lytic replication
cycle (figure 5A). The efficiency of silencing the expression of
MAP4K4, MMP-7 and MMP-13 with siRNA was controlled by
Western blot analysis for MAP4K4 (figure 5B) and qPCR for
MMP-7 and MMP-13 (figure 5C). We noted that silencing of
MAP4K4 led to a reduced expression of the early KSHV protein
KbZIP (figure 5B) and its mRNA transcript, as well as K8.1
mRNA expression (figure 5D), whereas silencing of MMP-7 and
MMP-13 had no effect on the protein and mRNA levels of KbZIP
(figure 5B, 5D) or mRNA levels of K8.1 (figure 5D). These
results suggest that MAP4K4 is involved in the activation of the
lytic replication cycle, which, in turn, promotes the expression of
MMP-7 and MMP-13.
MAP4K4-dependent COX-2 expression and enzymatic
activity is required for successful reactivation of KSHV
and the invasiveness of KSHV-infected endothelial cells
As shown in figure 4, silencing of MAP4K4 reduces the
expression of PTGS2, encoding cyclooxygenase 2 (COX-2). COX-
2 has previously been shown to be overexpressed in KSHV-
infected endothelial cells and to play a role in inflammation,
angiogenesis and invasion [20]. The KSHV K15 and vGPCR
proteins induce the expression of COX-2 [25,26]. COX-2
catalyses the production of prostaglandin E2 (PGE2) after
stimulation with inflammatory cytokines [80]. Depletion of
COX-2 reduced invasiveness of KSHV-infected endothelial cells,
similar to MAP4K4 knockdown (figure 6A). Interestingly, both
MAP4K4 and COX-2 silencing inhibited KSHV lytic reactivation
(figure 6B). To corroborate the effect of COX-2 depletion on
KSHV lytic reactivation, we used a specific inhibitor, which does
not affect constitutively active COX-1 [81]. Application of this
inhibitor, NS-398, led to a dramatic decrease, comparable to the
effect of MAP4K4 silencing, in the invasiveness of KSHV-infected
endothelial cells undergoing lytic reactivation (figure 6C). NS-
398 treatment not only led to a reduction of invasiveness, but also
effectively blocked KSHV lytic protein expression (figure 6D–E),
as well as the production of viral progeny (figure 6F). This
suggests that, in response to MAP4K4 signalling, COX-2
mediated production of PGE2 contributes to the successful
completion of KSHV lytic cycle and KSHV driven invasiveness
of infected endothelial cells.
MAP4K4 contributes to the invasiveness of primary
endothelial cells infected with KSHV
To extend our observations, which were obtained with the
immortalized endothelial cell line HuAR2T, to primary endo-
thelial cells, we investigated the role of MAP4K4 in the
invasiveness of human umbilical vein endothelial cells (HUVECs)
following their infection with rKSHV.219 (figure 7). On day 5
after infection, KSHV-infected HUVECs showed a markedly
increased invasiveness compared to uninfected cells, and this
increased invasiveness depended on the expression of MAP4K4,
since silencing of MAP4K4 with siRNA reduced their invasive-
ness to background levels (figure 7A–B). Similar to KSHV-
infected HuAR2T cells, expression of COX-2 increased after
infection of HUVECs with KSHV and silencing of MAP4K4 by
siRNA reduced COX-2 levels in KSHV-infected primary
endothelial cells (figure 7C). We also observed that after
infection with KSHV, MAP4K4 protein levels were moderately
increased (figure 7C–D). Moreover, KSHV lytic protein
expression was inhibited after MAP4K4 depletion in primary
cells, similarly to what we had found in immortalized endothelial
cells (figure 7D).
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MAP4K4 is expressed in KS spindle cells in vivo
To explore if MAP4K4 is expressed in KS tissue and could,
therefore, play a role in KSHV-infected cells in vivo and contribute
to the pathogenesis of KS, we stained KS biopsies with an
antibody to MAP4K4. We observed a strong expression of
MAP4K4 in the KS endothelial spindle cells, which are
characterised by the expression of CD34 and KSHV LANA
(figure 8A). Double staining for LANA and MAP4K4 confirmed
the strong cytoplasmic expression of MAP4K4 in LANA-
expressing cells (figure 8A). Individual staining for MAP4K4
and LANA of adjacent serial sections of a KS biopsy also indicated
the increased expression of MAP4K4 in LANA-expressing KS
spindle cells, although a lower level of MAP4K4 expression could
also be seen in other cells in the tumour (figure 8B–C), and a
basal expression of MAP4K4 was observed in the surrounding
connective tissue (figure 8C), in line with another report showing
low levels of MAP4K4 cytoplasmic staining in non-neoplastic lung
tissues, compared to strong expression in lung adenocarcinomas
[82]. We found a moderate to strong expression of MAP4K4 in
spindle cells in a total of 13 biopsies, derived from 11 patients
(figure 8D), confirming the consistent expression of this kinase in
KS tissue. This observation is consistent with a role for MAP4K4
and MAP4K4-dependent signalling pathways in the pathogenesis
of KS.
Discussion
In KS tumours, a small percentage (1–5%) of KSHV-infected
cells show evidence of viral lytic replication [31,83]. Taken
together with epidemiological findings indicating a beneficial effect
of inhibiting viral lytic replication on the incidence of KS in AIDS
patients [32] this suggests that lytic gene products may contribute
to the pathogenesis of this disease. On the one hand, lytic
replication can be a source of new virions and consequently newly
infected cells. This is important, as KSHV does not completely
immortalize spindle cells and needs to infect new cells to persist in
an infected host [33]. On the other hand, lytic reactivation may
lead to the production of autocrine and paracrine signalling
molecules, which then promote inflammation, angiogenesis, and
invasiveness. KSHV-infected endothelial spindle cells have been
shown to have invasive properties [16,20,69,84–86]. In order to
better understand how KSHV lytic replication cycle contributes to
the increased invasiveness of infected endothelial spindle cells we
investigated cellular mechanisms underlying the lytic switch of the
virus. In contrast to earlier studies that had employed siRNA
screens of the human kinome to identify cellular kinases involved
in KSHV reactivation and had identified Pim kinases as activators
of lytic replication [44], or Tousled-like kinases as negative
modulators of KSHV reactivation [87], we screened a library of
small molecule kinase inhibitors (figure 1A) to identify positive
regulators of KSHV lytic cycle. We found several compounds,
known to target p38 MAPK, to inhibit KSHV reactivation after
baculovirus RTA and Na-butyrate treatment (figure S1A), in line
with previous reports on a role of p38 during de novo infection [88],
after induction of productive reactivation [43], and during
progression of KSHV through the lytic cycle, when, for instance,
vGPCR activates p38 [89]. However, a close comparison of well-
characterized p38 inhibitors [90–94], showed that these com-
pounds varied with regard to their ability to inhibit KSHV
reactivation in endothelial cells, while showing comparable
efficacy in inhibiting the phosphorylation of the p38 MAPK
target MK2 (figure 1B). This observation suggested that some of
these compounds might also target other cellular kinases, which
could contribute to KSHV reactivation. Off-target effects of other
kinase inhibitors are well known and sometimes improve the
biological activity and clinical usefulness of individual compounds
[63,95]. Since compound SB220025, which is known to have anti-
inflammatory properties, proved to be the most efficient in
reducing KSHV lytic reactivation (figure 1B–C), we profiled this
substance together with VI18802, a derivative of SB220025,
against 442 kinases using the KINOMEscan platform (DiscoverX).
Extending previous reports on the ability of even ‘‘specific’’ p38
inhibitors to bind to other kinases [63], we found a range of other
kinases to be inhibited by SB220025 (figure S1B).
By blocking, among others, the p38 cascade, SB220025 inhibits
the production of IL-1b and TNF-a [91,96], and belongs to the
CSAID class of cytokine biosynthesis inhibitors [97,98]. However,
p38 is not the only regulator of inflammatory cytokine production.
JNKs also regulate the expression and activation of inflammatory
mediators, including TNF-a, IL-2, and MMPs [99,100]. Interest-
ingly, we identified several JNK isoforms and their putative
upstream activators MAP4K4 (NCK interacting kinase (NIK) or
haematopoietic/germinal centre kinase (HGK)), MINK (Misshap-
en/NIK related kinase), and TNIK (TRAF2 and NCK interacting
kinase) as targets of SB220025 (figure S1B). KSHV is known to
activate the JNK pathway during primary infection [101], and
JNK is essential for KSHV infection [58], and production of
inflammatory cytokines [31,101,102]. Considering the important
role of inflammation in KS development and progression, and the
dependence of KSHV on the JNK pathway, we investigated if
upstream regulators of JNK signalling targeted by SB220025
(MAP4K4/NIK, TNIK, MINK) are also critical for KSHV lytic
cycle. While siRNA-mediated knockdown of TNIK and MINK
did not affect KSHV reactivation (data not shown), MAP4K4
silencing reduced KSHV virus production (figure 2A), lytic
protein expression (figure 2B), and KSHV replication
(figure 2C) in immortalized, as well as primary endothelial cells
(figure 7D). Interestingly, vIL-6 expression levels were increased
Figure 4. Identification of cellular genes regulated by MAP4K4 signalling in KSHV-infected endothelial cells. HuAR2T rKSHV.219 cells
were transfected with control siRNA or siRNA targeting MAP4K4 twenty-four hours before the induction of the lytic cycle. Cells were harvested
twenty-four hours after inducing the lytic cycle. (A) Alterations in cellular gene expression following MAP4K4 knockdown and KSHV lytic reactivation.
54 cellular genes regulated by MAP4K4 (columns 4–6; grey scale) by a factor of .1.5 were identified by comparing their expression in lytically
induced HuAR2T rKSHV.219 cells silenced for MAP4K4 expression with control siRNA treated induced cells. The effect of lytic KSHV reactivation on
cellular gene expression is shown on a red-green scale in cells treated with either control siRNA (‘control/control’) or MAP4K4 siRNA (‘MAP4K4/
MAP4K4’) (columns 7–12). Uninfected HuAR2T cells were analysed in two additional experiments to evaluate the effects of the induction compounds
in the absence of KSHV (columns 13–14). Data were ordered according to the average fold induction strength in control siRNA treated HuAR2T
rKSHV.219 cells after lytic induction (columns 7, 9, 11). The fold ratios for PTGS2 presented in columns 7 to 12, which show induced/uninduced ratios
from control siRNA treated samples (columns 7, 9, 11) versus siMAP4K4 treated samples (columns 8, 10, 12), appear to be similar. This is due to the
fact that COX-2 expression is reduced by a similar factor in uninduced and induced samples following MAP4K4 silencing. (B) qPCR analysis of COX-2,
MMP-7 and MMP-13 expression in HuAR2T rKSHV.219 using dually labelled probes presented as means 6SD of three independent experiments. The
p values were determined using a One-way ANOVA with Tukey’s multiple comparison post-test. p.0.05 (ns); p,0.05 (*); p,0.01 (**); p,0.001 (***).
(C) Western blot analysis of COX-2 expression before and after MAP4K4 depletion in latent and lytically induced HuAR2T rKSHV.219 cells. The blot is
one representative of five independent experiments with similar results.
doi:10.1371/journal.ppat.1003737.g004
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after MAP4K4 silencing (figure 2B). Although vIL-6 is a lytic
gene induced by RTA [103], it is known to be also regulated
independently of the lytic switch, for instance by interferon-a [66]
and microRNAs, such as miR-1293 [104]. Whether MAP4K4 also
regulates the latter factors needs to be further investigated, and
perhaps would explain the observed increase in vIL-6 expression
in the absence of MAP4K4.
As MAP4K4 was previously shown to be overexpressed in
multiple tumour cell lines and cancers [49–51,105,106], and also
implicated in tumour cell invasiveness [49,106], we investigated its
role in previously reported invasiveness of KSHV-infected
endothelial cells. We could observe that KSHV-infected immor-
talized endothelial cells possess a much more invasive phenotype
after the induction of the lytic cycle (figure 3A–B). This increased
invasiveness could be reduced by MAP4K4 silencing using siRNA
(figure 3C–E), demonstrating a role of MAP4K4 in invasive
KSHV-infected endothelial cells. Similarly, silencing of MAP4K4
reduced the increased invasiveness of KSHV-infected primary
umbilical vein endothelial cells (figure 7A–C).
The role of MAP4K4 in different cellular functions is only
incompletely understood. In order to identify genes, regulated by
MAP4K4 in the context of KSHV lytic reactivation, we performed
Figure 5. MMP7 and MMP13 are required for the invasiveness of KSHV-infected endothelial cells. HuAR2T or HuAR2T rKSHV.219 cells
were transfected with control siRNA or siRNA pools targeting MAP4K4, MMP7 or MMP13 twenty-four hours before the induction of the lytic cycle.
Thirty-six hours after lytic reactivation starved cells were analysed for invasiveness. (A) Invasion score determined by quantifying DAPI stained invasive
cells during latency and in the course of lytic reactivation and presented as means 6SD of four independent experiments. The p values were
determined using a One-way ANOVA with Tukey’s multiple comparison post-test. p.0.05 (ns); p,0.05 (*); p,0.01 (**); p,0.001 (***); p,0.0001
(****). (B) Western blot analysis of MAP4K4 and KbZIP expression in HuAR2T and HuAR2T rKSHV.219 cells. The blot is one representative of four
independent experiments with similar results. (C) qPCR analysis of MMP-7 and MMP-13 expression in HuAR2T and HuAR2T rKSHV.219 cells. The graph
is one representative of four independent experiments with similar results. (D) qPCR analysis of KbZIP and K8.1 mRNA expression in HuAR2T and
HuAR2T rKSHV.219 cells. The graph is one representative of four independent experiments with similar results.
doi:10.1371/journal.ppat.1003737.g005
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a microarray-based analysis after silencing MAP4K4 and inducing
the lytic cycle.
Among cellular genes known to affect migration/invasion, we
found PTGS2, encoding COX-2, to be downregulated after
MAP4K4 knockdown (figure 4A). Its mRNA and protein levels
were highly upregulated in induced KSHV-infected cells
compared to uninfected cells (figure 4A). Increased levels of
PGE2 in Kaposi’s sarcoma tissue compared to surrounding tissues
were reported already in 1992 [107]. In keeping with this
observation, KSHV infected immortalized dermal microvascular
endothelial cells display a strong increase in COX-2 expression
and PGE2 production early during de novo infection [20,23,24],
Figure 6. COX-2 enzymatic activity contributes to the successful reactivation of KSHV and the invasiveness of KSHV-infected
endothelial cells. HuAR2T rKSHV.219 cells were transfected with control siRNA, MAP4K4- or COX-2 targeting siRNA pools or treated with NS-398 or
vehicle control, and subsequently analysed for invasiveness and KSHV lytic protein expression. (A) Invasion score determined after MAP4K4 or COX-2
depletion by quantifying DAPI stained invasive cells. The graph is one representative of two independent experiments with similar results. (B)
Western blot analysis of MAP4K4, COX-2, KbZIP, and K8.1 expression. The blot is one representative of two independent experiments with similar
results. (C) Invasion score determined after MAP4K4 depletion or COX-2 chemical inhibition by quantifying DAPI stained invasive cells. The graph is
one representative of three independent experiments with similar results. (D) Western blot analysis of KSHV lytic protein expression after MAP4K4
silencing or treatment with COX-2 inhibitor NS-398. The blot is one representative of three independent experiments with similar results. (E) Western
blot analysis of KSHV lytic protein expression after treatment with COX-2 inhibitor NS-398. The blot is one representative of three independent
experiments with similar results. (F) KSHV titre determined by quantifying GFP positive HEK293 cells forty-eight hours after infection with
supernatants from untreated or NS-398 treated HuAR2T rKSHV.219 cells. The graph shows means 6SD of three independent experiments. The p
values were determined using a One-way ANOVA with Tukey’s multiple comparison post-test. p.0.05 (ns); p,0.05 (*); p,0.01 (**); p,0.001 (***);
p,0.0001 (****).
doi:10.1371/journal.ppat.1003737.g006
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when lytic replication may still take place [108]. Our finding
suggests that COX-2 activation is, at least in part, mediated by
MAP4K4 and is critical for KSHV lytic cycle progression, as
treatment with a specific COX-2 inhibitor NS-398 (figure 6E) or
COX-2 depletion (figure 6B) led to a dramatic decrease in
expression of KSHV lytic proteins. COX-2 inhibitors are known
to also block human cytomegalovirus replication [109,110], as
PGE2 enhances, for instance, CMV promoter activation [111].
COX-2 activation might also play a role in HHV-6 [112], MHV-
68 [113], and HSV-1 [114] replication. Of note, MAP4K4
expression levels after COX-2 depletion and its chemical
inhibition were slightly reduced (figure 6B, 6D–E). MAP4K4
expression is regulated by TNF-a through TNF receptor a [53],
the expression levels of which in turn depend on PGE2 activation
Figure 7. Increased MAP4K4 expression in KSHV-infected primary endothelial cells promotes their invasiveness. HUVEC were infected
with concentrated rKSHV.219 at an MOI of 20 and monitored for MAP4K4 and KSHV lytic protein expression and invasiveness. (A) Representative
images of invasive uninfected or rKSHV.219-infected HUVEC before and after MAP4K4 depletion. (B) Invasion score determined by quantifying DAPI
stained uninfected or rKSHV.219-infected HUVEC, before and after MAP4K4 depletion. The graph shows means 6SD of three independent
experiments. The p values were determined using a One-way ANOVA with Tukey’s multiple comparison post-test. p.0.05 (ns); p,0.05 (*); p,0.01
(**); p,0.001 (***); p,0.0001 (****). (C) Western blot analysis of MAP4K4, COX-2 and LANA expression in uninfected or infected HUVEC. The blot is
one representative of three independent experiments with similar results. (D) Western blot analysis of MAP4K4, LANA, ORF45 and KbZIP protein
expression after infection of HUVEC with rKSHV.219 and MAP4K4 depletion.
doi:10.1371/journal.ppat.1003737.g007
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[115]. Hence it is conceivable that, when PGE2 production is
downregulated by chemical inhibition of COX-2, MAP4K4 levels
can also decrease as expression of TNF receptors is reduced.
COX-2 is a known mediator of angiogenesis and tumour cell
invasiveness, as it leads to production of inflammatory cytokines,
growth factors, angiogenic factors, and MMPs in various tumours,
as well as in KSHV infected cells [20,77,116–122]. We could also
show that, similarly to MAP4K4 knockdown, COX-2 silencing or
chemical inhibition significantly reduces the invasiveness of
KSHV-infected endothelial cells (figure 6A, 6C).
We also found that MAP4K4 mediates the expression of MMP-
7 and MMP-13 (figure 4A–B), which both contribute to the
Figure 8. MAP4K4 is expressed in endothelial spindle cells in KS tumours. (A) Subepidermal Kaposi’s sarcoma [KS] surrounding and
infiltrating a non-neoplastic blood vessel [V]. The tumour cells express CD34 (red; the non-neoplastic endothelial cells of the blood vessel are CD34
positive, too) and nuclear LANA (dark brown), as well as cytoplasmic MAP4K4 (light red; double-staining). (B) Kaposi’s sarcoma completely replacing
the lymphatic tissue of a lymph node. Nuclear LANA protein expression is observed in 50–70% of tumour cells (dark-brown) and cytoplasmic MAP4K4
expression – in more than 95% of sarcoma cells (brown). (C) Kaposi’s sarcoma [KS] partly expressing LANA and infiltrating non-neoplastic
subepidermal connective tissue [CT] with a non-neoplastic blood vessel [V]. Strong cytoplasmic MAP4K4 positivity is seen in KS cells, while only weak
MAP4K4 expression is present in non-neoplastic endothelial cells [V]. All images are presented in 2506magnification. (D) Summary of MAP4K4
expression in 13 KS biopsies.
doi:10.1371/journal.ppat.1003737.g008
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invasiveness of KSHV-infected cells (figure 5A). Although matrix
metalloproteinases are known to be modulated post-transcription-
ally [123–125], most of them, including MMP-7 and MMP-13,
can be activated also at the transcriptional level, as their promoters
harbour several cis-elements, allowing activation by trans-activa-
tors, e.g. NF-kB and AP-1 [126,127]. These MMPs can also be
induced at the mRNA level by TNF-a, IL-1 and other cytokines
[61,128–131]. Given that MAP4K4 regulates inflammatory
cytokine production, such as TNF-a and IL-1b [47], it may
therefore also modulate MMP-7 and MMP-13 mRNA expression.
Our observation that MAP4K4 regulates MMP-7 and MMP-13
expression illustrates its multifactorial role in the increased
invasiveness of KSHV-infected endothelial cells.
Given the reported role of MAP4K4 as an upstream activator of
JNK [64], and the role of JNK in KSHV reactivation [43], we also
explored if silencing of MAP4K4 in KSHV-infected endothelial
cells would alter the levels of JNK 1/2/3 phosphorylation, using
phospho-specific antibodies in Western blot analysis. However, we
could not detect any prominent effect of MAP4K4 silencing on the
levels of JNK phosphorylation (figure S3A), consistent with an
earlier report [47]. Searching for other cellular targets that would
be phosphorylated in response to MAP4K4, we employed a
commercial phosphokinase array and noted a moderate decrease
of c-Jun phosphorylation following MAP4K4 silencing (figure
S3B–C). This was confirmed in Western Blot analysis using an
antibody to c-Jun phosphorylated on S63 (figure S3D–E).
Phosphorylation of c-Jun may therefore provide another explana-
tion of how the upstream kinase MAP4K4 exerts its effect on
MMP-7 and MMP-13 expression. It might also lead to COX-2
overexpression. However, other possibilities remain to be inves-
tigated, as well as the mechanism of how MAP4K4 is activated in
KSHV-infected endothelial cells.
Having shown that MAP4K4-dependent signalling pathways
are involved in the increased invasiveness of KSHV-infected
primary and immortalized endothelial cells, we could demonstrate
that MAP4K4 is highly expressed in the pathognomonic KSHV-
infected endothelial spindle cells in KS lesions (figure 8A–D),
suggesting that it may indeed play a role in vivo in aspects of
KSHV-induced pathogenesis. Our findings also provide an




The use of the human biopsies and human umbilical cords for
this study was approved by the Hannover Medical School Ethics
Committee and conducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all patients.
Cells and transfections
HEK293 and EA.hy 926 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM), and Vero cells in minimal
essential medium (MEM) (Cytogen) supplemented with 10% foetal
bovine serum (HyClone), 50 U/ml penicillin, and 50 mg/ml
streptomycin (Cytogen) at 37uC in a 5% CO2 incubator. Human
umbilical vein endothelial cells (HUVEC) were isolated from
freshly obtained human umbilical cords by collagenase digestion of
the interior of the umbilical vein as described previously [132] and
were cultured in EGM-2MV medium (Lonza) at 37uC in a 5%
CO2 incubator. An endothelial cell line HuAR2T, conditionally
immortalized with doxycycline dependent human telomerase
reverse transcriptase (hTERT) and simian virus 40 (SV40) large
T antigen transgene expression [133], were maintained in
EGM-2MV medium in the presence of 200 ng/ml doxycycline.
Transfection with small interfering RNA (siRNA) was performed
using the Neon transfection system according to the manufactur-
er’s instructions (Invitrogen). All siRNAs were microporated at the
concentration of 100 pmol into 105 cells. The following siRNAs
(siGENOME SMARTpool) were obtained from Dharmacon,
Thermo Scientific: Control (Non-targeting siRNA Pool #2, D-
001206-14-20), MAP4K4 (M-003971-02-0005), MMP-7 (M-
003782-01-0005), MMP-13 (M-005955-01-0005).
Sf9 cells were maintained in Grace’s medium (Gibco) supple-
mented with 10% foetal bovine serum, 100 U/ml penicillin, and
50 mg/ml streptomycin (Cytogen) at 28uC. The generation of the
recombinant baculovirus expressing KSHV ORF50/RTA was
described previously [60].
Production of recombinant KSHV stocks
To produce virus stocks, Vero cells containing recombinant
KSHV (rKSHV.219) [60] were plated at 30–40% confluency in
T175 flasks and induced twenty-four hours later with 1 mM Na-
butyrate (Sigma-Aldrich) and 10% baculovirus coding for KSHV
ORF50/RTA. The supernatant was harvested 72 hours later and
0.45 mm filtered to remove cell debris. The cleared supernatant
was collected in centrifuge bottles (230 ml/bottle) and centrifuged
at 150006g at 4uC for 6 hours using a Type19 rotor (Beckman
Coulter). The supernatant was then discarded and the pellet
resuspended in 250 ml EBM2 basal medium (Lonza) overnight at
4uC. The resuspended virus was kept at 4uC for not longer than
three weeks.
For detection and quantification of KSHV titres, 2.36104
HEK293 cells were plated in a 96-well plate and infected with
serially diluted KSHV stocks. GFP-positive cells were counted two
days after infection. To determine KSHV titres from EA.hy
rKSHV.219 or HuAR2T rKSHV.219 cells after induction of the
lytic cycle, the supernatants were cleared from the debris by
0.45 mm filtration and applied to HEK293 cells without dilution.
Western blot analysis
Protein lysates of cells were prepared in 16SDS sample buffer
(62.5 mM Tris-HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM
DTT, 0.01% w/v bromophenol blue) supplemented with cOm-
plete Ultra protease inhibitor cocktail and PhosSTOP phosphatase
inhibitor cocktail (Roche). Proteins were resolved by SDS-PAGE,
transferred onto nitrocellulose membranes (GE Healthcare), and
detected using the following primary antibodies: rabbit polyclonal
MAP4K4 (HGK) antibody (#3485, Cell Signaling Technology),
rabbit polyclonal KSHV ORF50/RTA [37], mouse monoclonal
KSHV ORF45 antibody (sc-53883, Santa Cruz), mouse mono-
clonal HHV-8 KbZIP antibody F33P1 (sc-69797, Santa Cruz),
rabbit polyclonal KSHV vIL-6 antibody (13-214-050, Advanced
Biotechnologies), mouse monoclonal KSHV ORFK8.1A/B anti-
body (13-212-100, Advanced Biotechnologies), mouse monoclonal
b-actin antibody (A5441, Sigma-Aldrich), rabbit monoclonal
GAPDH antibody (#2118, Cell Signaling Technology), rabbit
polyclonal COX-2 antibody (#4842, Cell Signaling Technology),
rat monoclonal KSHV ORF73 (LNA-1) antibody (13-210-100,
Advanced Biotechnologies), mouse monoclonal phospho-JNK 1/
2/3 antibody 9H8 (sc-81502, Santa Cruz), rabbit polyclonal JNK
1/3 antibody C17 (sc-474, Santa Cruz), mouse monoclonal
phospho-p44/42 antibody (#9106, Cell Signaling Technology),
mouse monoclonal p44/p42 antibody 3A7 (#9107, Cell Signaling
Technology), rabbit polyclonal phospho-p38 antibody (#9211,
Cell Signaling Technology), rabbit polyclonal p38 antibody
(#9212, Cell Signaling Technology), rabbit monoclonal phos-
pho-MK2 antibody 27B7 (#3007, Cell Signaling Technology),
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rabbit polyclonal MK2 antibody (#3042, Cell Signaling Tech-
nology). All stainings were performed at 4uC overnight with
subsequent washing in TBS-T or PBS-T and incubation with a
corresponding secondary HRP-labelled antibody (DaKo) at RT
for one hour. Following further washing steps, the proteins were
detected with SuperSignal West Femto Chemiluminescent Sub-
strate (Pierce, Thermo Scientific).
Microarray-based mRNA expression analysis
The ‘‘Whole Human Genome Oligo Microarray V2’’ (G4845A,
ID 026652, Agilent Technologies) used in this study contains
44495 oligonucleotide probes covering roughly 27390 human
transcripts. Synthesis of Cy3-labeled cRNA was performed with
the ‘‘Quick Amp Labelling kit, one colour’’ (#5190-0442, Agilent
Technologies) according to the manufacturer’s recommendations.
cRNA fragmentation, hybridization, and washing steps were
carried out exactly as recommended in the ‘‘One-Color Micro-
array-Based Gene Expression Analysis Protocol V5.7’’ (Agilent).
Slides were scanned on the Agilent Micro Array Scanner
G2565CA (pixel resolution 5 mm, bit depth 20). Data extraction
and processing of raw fluorescence intensity values were
performed with the ‘‘Feature Extraction Software V10.7.3.1’’ by
using the recommended default extraction protocol file:
GE1_107_Sep09.xml.
Processed intensity values of the green channel (‘‘gProcessed-
Signal’’ or ‘‘gPS’’) were globally normalized by a linear scaling
approach: All gPS values of one sample were multiplied by an
array-specific scaling factor. This scaling factor was calculated by
dividing a ‘‘reference 75th Percentile value’’ (set as 1500 for the
whole series) by the 75th Percentile value of the particular
Microarray (‘‘Array i’’ in the formula shown below). Accordingly,
normalized gPS values for all samples (microarray data sets) were
calculated by the following formula: normalized gPSArray
i = gPSArray i X (1500/75th PercentileArray i). A lower intensity
threshold was defined as 1% of the reference 75th Percentile value
( = 15). All normalized gPS values below this intensity threshold
were substituted by the surrogate value of 15.
Data were filtered according to the following criteria: 1) More
than 1.5 fold downregulation in lytically induced HuAR2T
rKSHV.219 cells after MAP4K4 knockdown compared to control
siRNA treated induced cells (each of three experiments). 2)
Arithmetic mean intensity of nPS values calculated from both
channels that define ratio values .25 (each of three experiments).
3) QC flag entries ‘‘gIsNonUnifOL’’ (determined by the Feature
Extraction Software) must have been ‘‘0’’ (indicating reliable
performance) (each of six relevant channels of the three
experiments). 4) In cases, in which more than one probe directed
against the same transcript is present on the microarray, only those
transcripts passed the criteria, for which the majority of probes
indicate the respective regulation. 5) The respective transcript has
to be classified as being functionally characterized and reasonably
annotated (for details visit: www.mh-hannover.de/
Transcriptomics.html and consult our manual: ‘‘Crude probe
characterization_RCUT_date.pdf’’). Just one representative probe
is selected for visualization in figure 4A if many probes directed
against the same transcript match the applied criteria.
q(RT)-PCR analysis
Total RNA was extracted from the cells with an RNeasy kit
(QIAgen) according to the manufacturer’s recommendations,
followed by DNase treatment and inactivation (Ambion). cDNA
was synthesized using BioScript RNase H Low reverse transcrip-
tase (BIO-27036, Bioline) or Expand reverse transcriptase (Roche)
in 20 ml reactions. 1 ml of generated cDNA samples (50 ng total
RNA equivalents) were used per reaction for real-time PCR with
the ABI7500 system (Applied Biosystems). Specific amplification
was assured by utilizing TaqMan probes and gene specific
primers. Amplification was performed in 10 ml reactions with
TaqMan Fast Advanced Master Mix under recommended
conditions (Applied Biosystems; #4444557). The following Taq-
Man gene expression assays (Applied Biosystems: #4331182) were
used: Hs00153133_m1 (PTGS2/COX-2), Hs99999908_m1
(GUSB), Hs01042796_m1 (MMP-7), Hs00233992_m1 (MMP-
13), Hs02758991_g1 (GAPDH); primer-probe sets for RTA [134],
KbZIP [70], K8.1 [135]. The average Ct for each individual
amplification reaction was calculated from duplicate measure-
ments by means of the instrument’s software in ‘‘auto Ct’’ mode
(7500 System Software v.1.3.0). Average Ct values obtained for the
analysed transcripts of PTGS2/COX-2, MMP-7 or MMP-13
were normalized by subtraction from the Ct values obtained for
GUSB or GAPDH (housekeeping reference). Relative mRNA
expression changes were calculated according to the DDCt
method.
For quantification of KSHV genome copies, DNA was
extracted using the QIAamp DNA Blood Mini Kit (QIAgen)
according to the manufacturer’s instructions. KSHV genome copy
numbers were determined in a TaqMan based qPCR directed
against KSHV ORF K6 with normalization to the cellular C-
reactive protein (CRP) as described previously [136]. Briefly,
qPCR for KSHV was carried out in a total volume of 50 ml
containing a ready-to-use master mix (QuantiTect multiplex PCR
kit; Qiagen), 0.5 mM concentrations of each primer, 10 ml of DNA
from the sample of interest, and 0.4 mM FAM-labeled KSHV K6
probe. Amplification was performed in the Applied Biosystems
7500 thermal cycler and visualized with ABI 7500 software. qPCR
of CRP was carried out in a total volume of 20 ml containing a
ready-to-use master mix (LightCycler FastStart DNA Master
HybProbe; Roche), 0.3 mM MgCl2, 0.5 mM concentrations of
each primer, 0.2 mM FAM-labeled CRP probe, and 5 ml of DNA
from the sample of interest. Amplification was performed in the
LightCycler 2.0 Instrument and analyzed with the LightCycler
software. The primers (Sigma) and probes (Eurogentec) used for
the quantification of KSHV and CRP had the following
sequences: KSHV K6 forward (CGCCTA ATAGCTGCTGC-
TACGG), HHV8 K6 reverse (TGCATCAGCTGCCTAACC-
CAG), CRP forward (CTTGACCAGCCTCTCTCATGC), CRP
reverse (TGCAGTCTTAGACCCCACCC), K6 probe [59-(6
FAM)-CAGCCACCGCCCGTCCAAATTC-TAMRA], and
CRP probe [59-(6 FAM)-TTTGGCCAGACAGGTAAGGGC-
CACC-TAMRA].
In vitro invasion assay
Cell invasiveness was measured using Matrigel coated invasion
inserts (Growth Factor Reduced Matrigel Invasion Chamber,
8.0 mm; 354483, BD Biosiences). HuAR2T rKSHV.219 cells were
microporated with siRNAs twenty hours prior to the induction of
the lytic cycle. Twenty-four hours after the induction, the cells
were starved in EBM2 supplemented with 2% FCS for twelve
hours. Next day, 56104 cells were plated in the inner chambers in
500 ml of EBM2 basal medium with 2% FCS and 750 ml EBM2
was added to the outer chamber and incubated for twenty-four
hours. Before the assay, Matrigel inserts were rehydrated with
500 ml EBM2 for two hours. Cells that were able to degrade the
Matrigel layer, migrated to the lower surface of the filter, and were
fixed with 4% paraformaldehyde, permeabilised with 0.2% Triton
X-100, and nuclei were stained with DAPI (Sigma-Aldrich) and
counted under a fluorescent microscope. Four different Matrigel
chambers were used for each sample. Four random fields were
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counted for each chamber, and the average cell number per field
in a chamber was calculated using CellProfiler2.0. To quantify the
number of cells in the immunofluorescence images we used the
CellProfiler software [137]. All pixel intensities were rescaled to 0–
1. Using the Otsu Global thresholding method [138] in the DAPI
channel, the nuclear area was defined. Clumped nuclei were
distinguished based on the intensity. The threshold correction
factor was set to 1.3. Cell invasiveness of freshly isolated HUVECs
(,p. 2) was measured after infection with rKSHV.219 at MOI 30
for four days. Three days after infection the cells were
microporated with siRNAs and starved in EBM2 medium with
2% FCS. After twenty-four hours the cells were seeded onto the
Matrigel, and their invasiveness was quantified as described above.
Immunohistochemistry
3 mm thin tissue sections were cut from formalin-fixed KS
samples and stained with haematoxylin-eosin (HE). KS tumour
cells and non-neoplastic endothelial cells were marked immuno-
histochemically with anti-CD34 antibody (Menarini Corp.) using a
1:50 dilution. The KSHV latent nuclear antigen (LANA) was
marked immunohistochemically with NCL-HHV8-LNA anti-
body, clone 13B10, purchased from Novocastra, using a 1:50
dilution. MAP4K4 was stained immunohistochemically with
MAP4K4 monoclonal antibody M07, clone 4A5, produced by
Abnova Corp. and purchased from Biozol Diagnostica GmbH,
applied at a 1:300 dilution. When performing MAP4K4/LANA
double-staining, 1:20 (LANA) and 1:100 (MAP4K4) dilutions were
applied using the BenchMark Ultra staining machine.
Small molecule inhibitors and KINOMEscan
The library of kinase inhibitors was received from Vichem
Chemie Research Ltd. (Budapest, Hungary) as lyophilized
powders, and stored at room temperature. DMSO (cell culture
grade, Applichem) was used to dissolve the inhibitors at a stock
concentration of 10 mM. After reconstitution, the inhibitors were
stored at room temperature protected from light. VI18802 is a
phenoxypyrimidine [93] targeting p38a. As a part of the Vichem
Core Validation Library it was handled as described above.
SB203580 (#13067, Cayman Chemical), SB202190 (#EI-294-
0001, Biomol), SB220025 (#559396, Calbiochem), SKF86002
(#2008, Tocris Bioscience), and VX-745 (#3915, Tocris Biosci-
ence) were reconstituted and stored in working aliquots at 220uC
protected from light. To target COX-2, NS-398 (#349254,
Calbiochem) was prepared according to the manufacturer’s
recommendations and applied to the cells six hours before the
induction of the lytic cycle. Application of all compounds to the
cells was controlled by DMSO treatment.
For evaluation of KSHV reactivation inhibition, 56103 Vero
rKSHV.219 cells per well were plated in 96-well plates twenty-
four hours before the treatment with kinase inhibitors. The
inhibitors were applied one hour before the induction of the lytic
cycle. Forty-eight hours later the supernatants were transferred to
HEK293 cells, which were then centrifuged 30 min at 30uC and
5006g and incubated at 37uC for six hours. Medium was
exchanged, and the cells were incubated at 37uC for forty-eight
hours. The number of infectious particles was evaluated by the
mean fluorescence intensity of GFP-positive HEK293 cells.
Alternatively, Vero rKSHV.219 or EA.hy rKSHV.219 cells were
treated with kinase inhibitors, and subsequently with induction
mix to assess the expression levels of KSHV lytic proteins RTA
and K8.1.
To assay the viability of cells after treatment with kinase
inhibitors, each well of a 96-well plate received 20 ml glutaralde-
hyde (25%) and was incubated at RT for at least 20 min. After
washing with water, the plates were stained with 0.4% crystal
violet solution in methanol for 30 min. Absorbance at 590 nm was
measured spectrophotometrically with a reference to 405 nm
reading.
The KINOMEscan of SB220025 and VI18802 was carried out
by DiscoverX as described (www.discoverx.com).
Analysis of Ser/Thr kinase phosphorylation profiles
For evaluation of Ser/Thr kinase phosphorylation in endothe-
lial cells, a human phospho-kinase antibody array (ARY003B,
R&D Systems) was used according to the manufacturer’s
recommendations. Briefly, HuAR2T rKSHV.219 cells were
transfected with control siRNA or an siRNA pool targeting
MAP4K4 twenty-four hours before the induction of the lytic cycle.
Cells were lysed twenty-four after lytic cycle induction and diluted
lysates were applied to, and incubated overnight with, the
nitrocellulose membranes with spotted capture antibodies. The
array was washed to remove unbound proteins, followed by
incubation with a cocktail of biotinylated detection antibodies, and
streptavidin-HRP. Chemiluminescent detection reagents (Super-
Signal West Femto Chemiluminescent Substrate, 34096, Thermo
Scientific) were applied as recommended. The signal produced at
each capture spot corresponded to the amount of phosphorylated
protein bound.
Statistical analysis
Statistical analysis was performed using GraphPad prism
software. For the comparison of more than two groups a one-
way-ANOVA with Tukey’s post-test was applied after using
D’Agostino-Pearson’s normality test where applicable. P-values
,0.05 were considered as significant (*), ,0.01 (**), ,0.001 (***),
and ,0.0001 (****). P-values .0.05 were considered non-
significant (ns). Error bars were calculated from means 6SD.
The qPCR data are shown as means 6SEM, where one replicate
is shown as a representative.
Accession numbers
Akt (P31749), b-Raf (P15056), CD34 (P28906), CDC2L1
(A4VCI5), c-Jun (P05412), COX-1 (P23219), COX-2 (P35354),
CSNK1A1L (Q8N752), CSNK1D (P48730), CSNK1E (P49674),
ERK1 (P27361), IFN-a (P01562), IL-1b (P01584), IL-2 (P60568),
IL-6 (P05231), JNK1 (P45983), JNK3 (P53779), KSHV K15
(Q9QR69), KSHV K8.1 (D2XQF0), KSHV KbZIP (E5LBX3),
KSHV LANA (J9QT20), KSHV ORF45 (F5HDE4), KSHV
RTA (F5HCV3), KSHV v-Cyclin (Q77Q36), KSHV v-FLIP
(Q76RF1), KSHV vGPCR (Q98146), KSHV vIL-6 (Q98823),
MAP4K4 (O95819), MEK1 (Q02750), MINK (Q8N4C8), MK2
(P49137), MMP-1 (P03956), MMP-13 (P45452), MMP-19
(Q99542), MMP-2 (P08253), MMP-3 (P08254), MMP-7
(P09237), MMP-9 (P14780), NF-kB (Q04206), Notch (P46531),
p38a (Q16539), PI3K (P42336), Pim-1 (P11309), Pim-3
(Q86V86), PKA (P17612), PKCd (Q05655), RBP-Jk (Q06330),
STK36 (Q9NRP7), TLR7/8 (D1CS68), TNF-a (P01375), TNFR
a (P19438), TNIK (Q9UKE5).
Supporting Information
Figure S1 Effect of p38 inhibitors on KSHV production
and lytic protein expression. (A) Summary of 18 compounds
able to efficiently block KSHV production and late lytic protein
K8.1 expression in VK.219, BCBL1 and EA.hy rKSHV.219 cells.
(B) Identification of targets for SB220025 and VI18802 using the
KINOMEscan profiling platform. Target list of SB220025 and
VI18802 identified in this study, as compared to SB202190,
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SB203580, and VX745 [63]. Unique targets for SB220025 and
VI18802 are presented in grey fields.
(PDF)
Figure S2 Efficiency of MAP4K4 knockdown and its
effect on baculovirus RTA delivery. (A) Western blot analysis
of MAP4K4 and K8.1 expression levels in HuAR2T rKSHV.219
cells, transfected with control siRNA, an siRNA pool or individual
siRNAs targeting MAP4K4, and induced to reactivate KSHV for
forty-eight hours. (B) Schematic of individual siRNAs targeting
MAP4K4. (C) qPCR analysis of RTA expression from baculovirus
transduced into uninfected HuAR2T cells. The graph shows
means 6SD of three independent experiments. The p values were
determined using a One-way ANOVA with Tukey’s multiple
comparison post-test. p.0.05 (ns). (D) Western blot analysis of
MAP4K4 expression after siRNA silencing in uninfected
HuAR2T transduced with baculovirus coding for RTA. The blot
is one representative of two independent experiments with similar
results. (E) Efficiency of MAP4K4 knockdown in cells used for
microarray based gene expression analysis. HuAR2T rKSHV.219
cells were transfected with control siRNA or an siRNA pool
targeting MAP4K4 twenty-four hours before the induction of the
lytic cycle. Twenty-four hours after the lytic cycle induction cells
were harvested and lysed for subsequent analysis of protein
expression. Presented are the Western blots for MAP4K4 and
KSHV lytic protein expression.
(PDF)
Figure S3 Effect of MAP4K4 knockdown on putative
downstream phosphorylation targets. HuAR2T
rKSHV.219 cells were transfected with control siRNA or an
siRNA pool targeting MAP4K4, twenty-four hours before the
induction of the lytic cycle. Twenty-four to forty-eight hours after
the lytic cycle induction cells were harvested and lysed for
subsequent analysis of protein phosphorylation and expression. (A)
Western blot analysis of phosphorylated species of the indicated
proteins performed forty-eight hours after lytic cycle induction. (B)
Analysis of phosphorylation of Ser/Thr kinases with a human
phospho-kinase antibody array twenty-four hours after lytic cycle
induction. Positive and negative controls are encircled, and a
potential downstream target of MAP4K4 – c-Jun – is marked with
an arrow. (C) Quantification of results obtained with phospho-
kinase array. The signals from arrays as shown in panel B were
quantified in ImageJ and are presented as a mean 6SD of the
corresponding capture spots. (D) Verification of MAP4K4
knockdown efficiency in the cell lysates used for the human
phospho-kinase analysis. (E) Validation of the identified potential
downstream target of MAP4K4 by Western blot analysis of Ser63
c-Jun phosphorylation in HuAR2T rKSHV.219 twenty-four hours
after lytic cycle induction.
(PDF)
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